Skip to content
Search

Latest Stories

Omnicell secures deal with Hanmi Pharmaceutical to distribute new dispensing automation in Britain

Omnicell has expanded it existing range of automated medicines management and adherence solutions by entering into an agreement with Hanmi Pharm to distribute innovative tools across the UK’s retail pharmacy market.

The American healthcare technology company says the deal is "in line with Omnicell’s vision and appreciation that the retail pharmacy market wants choice through a more agnostic approach to automated medication adherence solutions."


The South Korean Hanmi Pharm-owned JVM model will support both blister and pouch adherence with the same level of detail and infrastructure Omnicell offers for its full range of solutions.

The model offers a flexible portfolio of hardware – from small desktop to large-scale models capable of handling between 300 to 576 cartridges – enabling it to meet the varying demands of pharmacies and allowing them to scale up or down models to suit their requirements.

“The JVM range of products provides an exceptional new offering for a variety of budgets across the retail pharmacy market, which further demonstrates Omnicell’s commitment to understanding and meeting the needs of our clients,” said Sara Dalmasso, general manager and vice president of Omnicell International.

“The last 18-24 months have placed immense pressure on the sector and this is another step in helping to make the day-to-day working lives of pharmacists easier and more efficient, and ultimately freeing up their valuable time to focus more on face-to-face patient interaction and care.”

The agreement is expected to expand Omnicell’s existing automated medication adherence solutions, while making it more accessible to different users.

Cyrus Hodivala, sales director, UK and Ireland, at Omnicell International, adds: “It is important for us to be constantly evolving our solutions in line with the changing dynamics of the retail pharmacy sector. Joining forces with Hamni Pharm – a leading, global pharmaceutical company – provides a welcome expansion of Omnicell’s portfolio for the UK market.

“With a shared and comprehensive expertise in the automation field, we are confident the new partnership will ensure Omnicell remains at the forefront of automation solutions. By enabling pharmacists to easily scale their business, our solutions will result in immediate improvements in medication adherence and patient outcomes.”

In January, Omnicell acquired Hub and Spoke Innovations.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less